HUE066216T2 - Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében - Google Patents
Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésébenInfo
- Publication number
- HUE066216T2 HUE066216T2 HUE17737132A HUE17737132A HUE066216T2 HU E066216 T2 HUE066216 T2 HU E066216T2 HU E17737132 A HUE17737132 A HU E17737132A HU E17737132 A HUE17737132 A HU E17737132A HU E066216 T2 HUE066216 T2 HU E066216T2
- Authority
- HU
- Hungary
- Prior art keywords
- parp2
- parp1
- tubulin
- inhibitors
- cancer
- Prior art date
Links
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000004243 Tubulin Human genes 0.000 title 1
- 108090000704 Tubulin Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150063226 parp-1 gene Proteins 0.000 title 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354449P | 2016-06-24 | 2016-06-24 | |
| US201662426095P | 2016-11-23 | 2016-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066216T2 true HUE066216T2 (hu) | 2024-07-28 |
Family
ID=59297390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17737132A HUE066216T2 (hu) | 2016-06-24 | 2017-06-23 | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11072600B2 (OSRAM) |
| EP (1) | EP3475272B1 (OSRAM) |
| JP (2) | JP7033588B2 (OSRAM) |
| KR (1) | KR102494294B1 (OSRAM) |
| CN (1) | CN109843874B (OSRAM) |
| AU (1) | AU2017280334C1 (OSRAM) |
| ES (1) | ES2964531T3 (OSRAM) |
| HU (1) | HUE066216T2 (OSRAM) |
| IL (1) | IL263917B (OSRAM) |
| MX (2) | MX387726B (OSRAM) |
| PL (1) | PL3475272T3 (OSRAM) |
| PT (1) | PT3475272T (OSRAM) |
| SG (1) | SG11201811393WA (OSRAM) |
| WO (1) | WO2017223516A1 (OSRAM) |
| ZA (2) | ZA201808562B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
| CN108884054B (zh) | 2015-11-30 | 2022-08-02 | 儿童医学中心公司 | 用于治疗增殖性疾病的化合物 |
| ES2964531T3 (es) | 2016-06-24 | 2024-04-08 | Univ California | Derivados de ftalazina como inhibidores de PARP1, PARP2 y/o tubulina útiles para el tratamiento del cáncer |
| JP7372253B2 (ja) | 2018-04-05 | 2023-10-31 | ノビガ・リサーチ・エービー | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401171A (en) | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
| SU1019810A1 (ru) | 1981-07-28 | 1991-04-07 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью |
| SU1218649A1 (ru) | 1984-09-19 | 1991-04-30 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы |
| AU2720199A (en) | 1998-02-03 | 1999-08-23 | Boehringer Ingelheim Pharma Kg | Five-membered, benzo-condensed heterocycles used as antithrombotic agents |
| AU3076700A (en) | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
| DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
| IL155645A0 (en) | 2000-10-30 | 2003-11-23 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| EP1633724B1 (en) | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7846959B2 (en) | 2004-05-07 | 2010-12-07 | Exelixis, Inc. | Raf modulators and methods of use |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CN101291928A (zh) * | 2005-10-19 | 2008-10-22 | 库多斯药物有限公司 | 4-杂芳甲基取代的酞嗪酮衍生物 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| SI2271626T1 (sl) * | 2008-03-27 | 2015-03-31 | Janssen Pharmaceutica, N.V. | Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina |
| CA3012137A1 (en) | 2010-01-29 | 2011-08-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2714703B1 (en) | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| KR101546743B1 (ko) * | 2012-01-16 | 2015-08-24 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| SG11201503670YA (en) * | 2012-12-31 | 2015-07-30 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| ES2964531T3 (es) * | 2016-06-24 | 2024-04-08 | Univ California | Derivados de ftalazina como inhibidores de PARP1, PARP2 y/o tubulina útiles para el tratamiento del cáncer |
-
2017
- 2017-06-23 ES ES17737132T patent/ES2964531T3/es active Active
- 2017-06-23 SG SG11201811393WA patent/SG11201811393WA/en unknown
- 2017-06-23 JP JP2019519615A patent/JP7033588B2/ja active Active
- 2017-06-23 KR KR1020197002267A patent/KR102494294B1/ko active Active
- 2017-06-23 WO PCT/US2017/039119 patent/WO2017223516A1/en not_active Ceased
- 2017-06-23 MX MX2018015893A patent/MX387726B/es unknown
- 2017-06-23 US US16/310,606 patent/US11072600B2/en active Active
- 2017-06-23 PT PT177371325T patent/PT3475272T/pt unknown
- 2017-06-23 AU AU2017280334A patent/AU2017280334C1/en active Active
- 2017-06-23 PL PL17737132.5T patent/PL3475272T3/pl unknown
- 2017-06-23 HU HUE17737132A patent/HUE066216T2/hu unknown
- 2017-06-23 IL IL263917A patent/IL263917B/en unknown
- 2017-06-23 CN CN201780051422.3A patent/CN109843874B/zh active Active
- 2017-06-23 EP EP17737132.5A patent/EP3475272B1/en active Active
-
2018
- 2018-12-17 MX MX2021013641A patent/MX2021013641A/es unknown
- 2018-12-19 ZA ZA2018/08562A patent/ZA201808562B/en unknown
-
2019
- 2019-07-30 US US16/526,620 patent/US10640493B2/en active Active
-
2021
- 2021-07-15 US US17/376,577 patent/US12145925B2/en active Active
- 2021-11-26 JP JP2021192564A patent/JP2022037004A/ja active Pending
-
2023
- 2023-01-25 ZA ZA2023/01066A patent/ZA202301066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7033588B2 (ja) | 2022-03-10 |
| KR20190033534A (ko) | 2019-03-29 |
| US11072600B2 (en) | 2021-07-27 |
| MX2018015893A (es) | 2019-08-01 |
| MX2021013641A (es) | 2022-01-06 |
| AU2017280334A1 (en) | 2019-01-17 |
| ES2964531T3 (es) | 2024-04-08 |
| WO2017223516A1 (en) | 2017-12-28 |
| CN109843874B (zh) | 2022-05-27 |
| KR102494294B1 (ko) | 2023-01-31 |
| JP2022037004A (ja) | 2022-03-08 |
| US20220402894A1 (en) | 2022-12-22 |
| JP2019522681A (ja) | 2019-08-15 |
| ZA202301066B (en) | 2024-05-30 |
| BR112018076821A2 (pt) | 2019-04-02 |
| ZA201808562B (en) | 2023-12-20 |
| PT3475272T (pt) | 2023-12-15 |
| US10640493B2 (en) | 2020-05-05 |
| MX387726B (es) | 2025-03-18 |
| EP3475272A1 (en) | 2019-05-01 |
| US20190337928A1 (en) | 2019-11-07 |
| IL263917B (en) | 2022-07-01 |
| CA3029004A1 (en) | 2017-12-28 |
| AU2017280334B2 (en) | 2021-07-29 |
| PL3475272T3 (pl) | 2024-04-29 |
| EP3475272B1 (en) | 2023-09-13 |
| AU2017280334C1 (en) | 2022-10-20 |
| US20190352283A1 (en) | 2019-11-21 |
| IL263917A (en) | 2019-02-28 |
| US12145925B2 (en) | 2024-11-19 |
| SG11201811393WA (en) | 2019-01-30 |
| CN109843874A (zh) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| IL272948A (en) | ENPP1 inhibitors and their use for cancer treatment | |
| LT3902803T (lt) | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| HUE053449T2 (hu) | Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében | |
| HUE055635T2 (hu) | Probiotikumok alkalmazása a pikkelysömör kezelésben és/vagy megelõzésében | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| HUE059990T2 (hu) | 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként | |
| HUE066216T2 (hu) | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében | |
| SI3268374T1 (sl) | KV1.3 inhibitorji in njihova medicinska uporaba | |
| HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
| IL265961A (en) | Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing | |
| EP3487492A4 (en) | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| HUE060882T2 (hu) | Naftiridinon-származékok és alkalmazásuk arrhytmia kezelésében | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| HUE057216T2 (hu) | Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében | |
| HUE067036T2 (hu) | 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében | |
| IL250708A0 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
| PL3630112T3 (pl) | Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| HUE047272T2 (hu) | Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére |